Retatrutide Beats Semaglutide in Diabetes Trial
Lilly disclosed 80-week Phase III TRANSCEND-T2D-2 topline results on 28 October: retatrutide improved A1C and weight more than semaglutide 2 mg in adults with inadequately controlled type 2 diabetes. The investigational triple agonist is…
